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Introduction
Immune thrombocytopenic purpura
(ITP), formerly known as idiopathic
thrombocytopenic purpura, is a
relatively rare, but potentially life
threatening autoimmune disorder that
involves the destruction of platelets by
autoantibodies. The resultant
decreased platelet count leaves the
patient at risk for excessive bruising
and bleeding (Hunt, 2010). ITP can
occur in both adults and children, and
also occurs as an acute or chronic
disorder. It is thought that the cause of
acute ITP may differ from that of
chronic ITP, however, the underlying
disease processes that occur are very
similar (Johnsen, 2012). Acute ITP, the
most common form of the disease, most
often occurs in children (Hunt, 2010).
It is estimated that acute ITP occurs in
as many as 6.4 per 100,000 children per
year (Deane, 2014). Most children
diagnosed with acute ITP have a history
of a recent viral infection, usually
occurring three to four weeks prior to
diagnosis. The majority of cases are
relatively mild and nearly 50 percent of
these cases will resolve within two
months. The most serious, but very
rare, complication of ITP is intracranial
hemorrhage (Maher, 2014).
Throughout my experience in
pediatric hematology/oncology, I have
cared for a number of patients
diagnosed with acute ITP. Although ITP
is generally treated by specialists in
hematology, most patients present to
their primary care practitioner with the
onset of signs and symptoms.
Thrombocytopenia can also be seen in
other hematological and oncological
diseases and often, ITP is a diagnosis of
exclusion. It is important that primary
care practitioners that treat both adults
and children recognize the presenting
symptoms of this disease to begin the
proper work-up. Although this disorder
is rare, it is essential for practitioners to
be aware of this condition to consider it
as a potential diagnosis and identify
patients at risk for severe complications
of the disease.

Pathophysiological Processes
Acute ITP is a complex autoimmune
disorder characterized by isolated
thrombocytopenia. ITP can involve both
increased platelet destruction and
decreased platelet production (Kime,
Klima, Rose & O’Brien, 2013). ITP
results from autoantibody
immunoglobulin G (IgG) binding to
glycoproteins, typically GPIIb/IIIa, on
the surface of the platelets (Bredlau,
Semple, & Segel, 2011). IgG that is
bound to circulating platelets serves as
an opsonin (a molecule that enhances
phagocytosis by marking an antigen for
an immune response) and induces
increased platelet phagocytosis and
destruction by mononuclear
macrophages primarily occurring in the
spleen (Lo & Deane, 2014). Anti-platelet
antibodies also combine with the antigen
to form an immune complex which leads
to activation of complement, and results
in phagocytosis and increased lysis of
platelets (Johnsen, 2012).
Acute ITP is often preceded by a viral
infection which is thought to trigger this
autoimmune response. The concept of
antigenic mimicry may occur in
response to this viral infection. The
antigen on the viral surface may closely
resemble the antigen on the platelet
surface leading to the antibodies
recognizing the platelets as foreign
resulting in platelet removal by
phagocytosis (Abadi, YarchovskyDolberg & Ellis, 2015).
Recent research has shown that with
ITP, there is also a dysfunction of
megakaryocytes (large cells in the bone
marrow that break into fragments that
become platelets). Megakaryocyte
production and differentiation is
stimulated by the hormone
thrombopoietin. Thrombopoietin is
secreted by the liver in response to
alterations in platelet count, however,
this response is impaired in patients
with ITP (Lu & Nossent, 2015). This
impaired production of thrombopoietin
leads to abnormalities in
megakaryocytes and a decreased
production of platelets (Labarque &
Geet, 2014). The IgG autoantibodies
may also bind with proteins on the
membrane of megakaryocytes impairing
the fragmentation of megakaryocytes
into platelets and inducing apoptosis
(Maher, 2014).

Figure 1. Coating of Platelets with
Autoantibodies. This figure shows
the binding of IgG to platelet surface.
Adapted from “Idiopathic
thrombocytic purpura”, by D.
Winkeljohn, 2010, 14(4), p. 411.
Acute ITP is usually a self-limiting
disorder that resolves within six
months, but it can progress to the
chronic form of the disorder which
patients may deal with for a lifetime.
While the exact etiology of ITP is
unknown, acute ITP is often preceded
by a viral infection a few days or weeks
prior to the onset of symptoms. The
majority of the time, no pathogen is
identified but in a small number of
cases, Epstein-Barr virus, influenza and
varicella-zoster virus have been
detected. ITP is also a known, but very
rare complication of the measlesmumps-rubella vaccine (Johnsen,
2012). This complication corresponds
with the concept of antigenic mimicry
or provocation of the immune system
resulting in an autoimmune response.
Patients with one autoimmune disease
are at a higher risk of developing a
second autoimmune disease. ITP has
been shown to arise in individuals with
systemic autoimmune diseases such as
systemic lupus erythematous and
rheumatoid arthritis (Johnsen, 2012).
ITP occurs with varying levels of
thrombocytopenia. Patients that
present without any signs of active
bleeding and a platelet count greater
than 10,000/mm³ usually do not
require treatment (Buchanan, 2014).
However, patients with platelet counts
less than 10,000/mm³, active bleeding,
comorbidities, or any risk for trauma
will be treated with drug therapies
(Bredlau, Semple & Segal, 2011).

Case Study
A mother brought her previously healthy two-year-old son to his primary care
provider with concerns about sudden onset scattered bruising to his bilateral legs, arms
and trunk, purple freckles to his bilateral upper extremities, and a twenty minute
nosebleed. The patient’s mother denied that her son had experienced any pain, fever,
fatigue, recent weight loss, headache, or recent trauma. The patient had a positive history
of upper respiratory infection about three weeks ago per the patient’s mother. The
patient's mother reported no relevant past medical history, no current medication use, and
no family history of bleeding disorders or cancers.
On physical exam, the patient was noted to be very active with vital signs within
normal limits for the patient’s age. Temperature 99.0°F, heart rate 114 beats/minute,
blood pressure 92/58, respiratory rate 28 breaths/minute, and oxygen saturation of 99%
on room air. No pallor was noted, but significant scattered ecchymosis and petechiae were
present to patient’s trunk and bilateral upper and lower extremities. The remainder of the
physical exam was normal, specifically no lymphadenopathy, splenomegaly, or
hepatomegaly were noted (Labarque & Geet, 2014).
A complete blood count (CBC) was obtained and examination of peripheral blood
smear was performed (Labarque & Geet, 2014). The patient’s CBC showed a normal white
blood cell (WBC) count of 6,800/mm³, normal hemoglobin (Hgb) of 13.7g/dl, and a
decreased platelet count of 17,000/mm³. The peripheral blood smear appeared normal
with the exception of an increase in average platelet size (Maher, 2014).

Nursing Implications

Signs and Symptoms

Acute ITP is a disorder that is most
often managed by specialists in
hematology. All nursing professionals
should have a general understanding of
the disease process because nurses of all
levels and specialties may come in
contact with this disorder at some time.
Patients are likely to present to their
primary care provider with the onset of
signs and symptoms of ITP. This
provider should be able to recognize and
identify the potential for this disorder
and also have an understanding of the
potential complications that may arise as
a result of ITP. Having this
understanding is essential to performing
appropriate testing and making
recommendations for further
management including possible referral
to a specialist. Although the cause of ITP
is still under investigation, certain
infections and vaccinations do precede
some cases. Patients diagnosed with
other autoimmune disorders are also
more likely to develop ITP throughout
their lifetime (Johnsen, 2012). The
increased risk for bleeding associated
with ITP can also place patients at a
much higher risk of developing bleeding
complications from medical procedures
(Hunt, 2010). To implement appropriate
interventions that can prevent
complications from these procedures, an
understanding of ITP is necessary.

ITP is often a diagnosis of exclusion
and patients can present with no obvious
symptoms. ITP is generally defined by a
platelet count of less than 100,000/mm³
(Lo & Deane, 2014). The
thrombocytopenia can be an incidental
finding on a routine CBC because signs
and symptoms associated with ITP may
not be apparent until the platelets drop
below 30,000/mm³.
Acute ITP usually has an abrupt onset
of symptoms and can occur in otherwise
healthy individuals (Maher, 2014).
Common signs of ITP are easy bruising,
petechiae, prolonged bleeding from cuts
or scrapes, epistaxis, menorrhagia, and
mucosal bleeding (Hunt, 2010). Blood
may be present in the urine, stool, or
sputum, but this is much less common
(Maher, 2014). Intracranial hemorrhage
is the most dangerous, but very rare
complication of ITP. Individuals with
intracranial hemorrhage may complain of
headaches, blurry vision, or display a
change in or loss of consciousness.
Individuals that present with mucosal
bleeding are more likely to experience
intracranial hemorrhage (Hunt, 2010).

Conclusion

Figure 2. Model of relationship of
contributing factors in ITP. Adapted
from “Pathogenesis in immune
thrombocytopenia : New insights”, by J.
Johnsen, 2012, . American Society of
Hematology, 2012(1), p. 310.

ITP is an autoimmune disorder in
which the body attacks its own platelets.
ITP occurs in both an acute and chronic
form. Acute ITP typically occurs in
otherwise healthy children but can also
occur in teenagers and adults of all ages.
Acute ITP is associated with a sudden
onset of symptoms (Maher, 2014). This
disorder is associated with an increased
risk for bleeding and therefore, increased
awareness and recognition of this
disorder is key to avoiding the potential
complications.
Figure 3. Petechiae and
Purpura. Bleeding under the
skin causes the red and purple
discoloration. Cleveland Clinic
Foundation (2012) Retrieved
from
http://my.clevelandclinic.org

.
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